Featured Research

from universities, journals, and other organizations

Rethinking body mass index (BMI) for assessing cancer risk

Date:
November 8, 2012
Source:
Albert Einstein College of Medicine of Yeshiva University
Summary:
A new study suggests that body mass index (BMI) -- the most commonly used weight-for-height formula for estimating fatness -- may not be the best measure for estimating disease risk, and particularly the risk of certain types of cancer.

A study by researchers at Albert Einstein College of Medicine of Yeshiva University suggests that body mass index (BMI) -- the most commonly used weight-for-height formula for estimating fatness -- may not be the best measure for estimating disease risk, and particularly the risk of certain types of cancer.

The study was published today in the online edition of the American Journal of Epidemiology.

BMI is calculated by dividing a person's weight (in kilograms) by his or her height in meters squared, or W/H2. Most of the early studies that used the formula, starting roughly sixty years ago, were conducted among middle-aged men. BMI has become the most widely-used weight-for-height index in large population studies of children and adults, thanks mainly to its ease of calculation and the ready availability of weight and height data. Newer technologies have since been developed for measuring body fat, but they can be prohibitively expensive and time consuming.

A BMI between 18.5 and 24.9 is considered ideal; obesity is defined as a BMI of 30 or greater. According to the Centers for Disease Control and Prevention, the higher one's BMI, the greater the risk for a range of diseases, including heart disease, high blood pressure, type 2 diabetes and certain cancers.

"It has long been recognized that BMI is an imperfect indicator of body fat because weight does not distinguish between lean body mass (muscle, bones, blood, water) and fat mass," said lead author Geoffrey C. Kabat, Ph.D., senior epidemiologist in the department of epidemiology & population health at Einstein. "This means that two individuals can have the same BMI but can have very different percentage of body fat." Furthermore, when using weight and height data, a single BMI formula may not be appropriate for all populations and all diseases."

The goal of the current study was to determine whether alternative weight-for-height measures resulted in stronger associations with risk of specific cancers compared to BMI. Using weight and height data on nearly 90,000 Canadian women enrolled in the Canadian National Breast Screening Study, the researchers varied the BMI formula -- changing the value of x in W/Hx -- to see whether any of these variations on BMI better predicted the risk of 19 different cancers.

All values of x in W/Hx that showed significant associations with specific cancers were below the value of 2.0 (i.e., BMI) and included 0.8 for endometrial cancer, 1.3 for lung cancer in those who never smoked, and 1.7 for postmenopausal breast cancer.

While these findings need to be confirmed in other studies, they suggest that the optimal value of W/Hx may differ depending on the population studied as well as on the disease of interest, and that BMI may not be optimal for all purposes.

Dr. Kabat's paper is titled "Scaling of weight-to-height in relation to risk of cancer at different sites in a cohort of Canadian women." Other contributors include Moonseong Heo, Ph.D., and senior author Thomas E. Rohan, M.D., Ph.D., both at Einstein, and Anthony B. Miller, M.B., at the University of Toronto, Canada.


Story Source:

The above story is based on materials provided by Albert Einstein College of Medicine of Yeshiva University. Note: Materials may be edited for content and length.


Journal Reference:

  1. Geoffrey C. Kabat, Moonseong Heo, Anthony B. Miller, and Thomas E. Rohan. Scaling of Weight for Height in Relation to Risk of Cancer at Different Sites in a Cohort of Canadian Women. American Journal of Epidemiology, 2012; DOI: 10.1093/aje/kws270

Cite This Page:

Albert Einstein College of Medicine of Yeshiva University. "Rethinking body mass index (BMI) for assessing cancer risk." ScienceDaily. ScienceDaily, 8 November 2012. <www.sciencedaily.com/releases/2012/11/121108073637.htm>.
Albert Einstein College of Medicine of Yeshiva University. (2012, November 8). Rethinking body mass index (BMI) for assessing cancer risk. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2012/11/121108073637.htm
Albert Einstein College of Medicine of Yeshiva University. "Rethinking body mass index (BMI) for assessing cancer risk." ScienceDaily. www.sciencedaily.com/releases/2012/11/121108073637.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins